Hôpital de la Croix-Rousse - Academic Profile

Publications

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

2019 The Lancet Oncology 1593 citations

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You Li , Xin Wang , Dianna M. Blau +97 more

EU Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).

2022 The Lancet 1529 citations

Affiliated Researchers

Philippe Merle

Hôpital de la Croix-Rousse

Institution Info

Type: healthcare
Country: FR
Publications: 3
Citations: 9,586

External Links

Identifiers

ROR: https://ror.org/006evg656